ArticleCardiovascular diabetology2025
Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics-driven precision medicine.iMeta · 2026Review
- State-Dependent DNA Methylation Signatures Distinguish Acute from Stable Coronary Syndromes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundCoronary angiography remains the gold standard for diagnosing coronary artery disease (CAD), but its invasive nature limits its applicability for widespread screening. Identifying non-invasive molecular markers could improve CAD classification and risk assessment.
methodsWe employed 5hmC-Seal technology to generate genome-wide 5-hydroxymethylcytosine (5hmC) profiles from plasma cell-free DNA (cfDNA) in 724 CAD patients, stratified into stable CAD (sCAD), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI) groups. Using machine learning algorithms, we identified inflammation-related 5hmC modifications associated with disease severity and constructed a classification model based on key hydroxymethylated markers. The model was validated internally and externally in an independent cohort of 167 patients.
resultsWe found that inflammation-related differentially hydroxymethylated genes (DhMGs) were significantly associated with CAD severity, with enriched pathways linked to immune activation and inflammatory response regulation. A 19-marker panel of 5hmC-based features effectively distinguished CAD patients at different disease stages, with high classification accuracy (AUC = 0.913 in the internal validation cohort). External validation confirmed the robustness of the model, achieving AUCs of 0.784, 0.880, and 0.918 when differentiating between NCA vs. sCAD, sCAD vs. MI, and NCA vs. MI, respectively. Compared to traditional clinical indicators, the 5hmC-based model demonstrated superior discriminatory power for MI.
conclusionsOur findings suggest that 5hmC modifications in cfDNA reflect CAD-related epigenetic changes and may serve as a promising biomarker for disease stratification. These results provide new insights into the epigenetic landscape of CAD and highlight the potential utility of 5hmC profiling for non-invasive disease monitoring. Further studies are warranted to validate these findings and explore their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.